Table 1.
Baseline Characteristics
| Variable | Metoclopramide 10mg (n=113) | Metoclopramide 20mg (n= 118 ) | Metoclopramide 40mg (n=118 ) |
|---|---|---|---|
| Age in years (mean, SD) | 39 (11) | 37 (10) | 38 (12) |
| Female | 83% (75, 89%) | 87% (80, 92%) | 82% (74, 88%) |
| Race* | |||
| Black/African American | 28% (21, 37%) | 28% (21, 37%) | 20% (14, 28%) |
| Latino/Hispanic | 70% (61, 78%) | 70% (61, 78%) | 76% (68, 83%) |
| Asian/Pacific Islander | 0% (0, 4%) | 1% (0, 5%) | 1% (0, 5%) |
| White | 18% (12, 26%) | 20% (14, 28%) | 19% (13, 27% |
| Headache duration in hours (median, IQR) | 48 (19, 72) | 68 (24, 96) | 24 (14, 72) |
| Aura symptoms | 27% (20, 36%) | 32% | 27% (20, 36%) |
| Median pain score (0–10) at baseline (IQR) | 8 (7, 10) | 9 (7, 10) | 9 (8, 10) |
| Took migraine/headache medication prior to ED presentation | 57% (48, 66%) | 68% (59, 76%) | 64% (55, 72%) |
| Median days of functional disability (IQR)** | 4 (2, 10) | 4 (1, 9) | 4 (2, 7) |
Reported as percent and 95%CI unless otherwise noted
*
Race: Some patients were multi-racial
**
“How many headaches have you had in the last 90 days that were so severe you were unable to do most of your usual daily activities?”